Ex Vivo Perfusion With Methylprednisolone Attenuates Brain Death-induced Lung Injury in Rats.
Journal
Transplantation direct
ISSN: 2373-8731
Titre abrégé: Transplant Direct
Pays: United States
ID NLM: 101651609
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
29
10
2020
revised:
24
01
2021
accepted:
02
02
2021
entrez:
22
3
2021
pubmed:
23
3
2021
medline:
23
3
2021
Statut:
epublish
Résumé
The onset of brain death (BD) leads to the deterioration of potential donor lungs. Methylprednisolone is considered to increase lung oxygenation capacity and enhance the procurement yield of donor lungs, when applied in situ, during donor management. However, whether BD-induced lung damage is ameliorated upon treatment with methylprednisolone during acellular ex vivo lung perfusion (EVLP), remains unknown. We aimed to investigate whether the quality of lungs from brain-dead donors improves upon methylprednisolone treatment during EVLP. Rat lungs were randomly assigned to 1 of 3 experimental groups (n = 8/group): (1) healthy, directly procured lungs subjected to EVLP; (2) lungs from brain-dead rats subjected to cold storage and EVLP; and (3) lungs from brain-dead rats subjected to cold storage and EVLP with 40 mg methylprednisolone added to the perfusate. Ventilation and perfusion parameters, histology, edema formation, metabolic profile, and inflammatory status of lungs were investigated. Methylprednisolone treated lungs from brain-dead donors improved positive inspiratory pressures needed to maintain tidal volumes of 7 mL/kg of body weight, which was 25.6 ± 5.8 cm H We showed that methylprednisolone treatment during EVLP attenuates BD-induced lung injury.
Identifiants
pubmed: 33748411
doi: 10.1097/TXD.0000000000001141
pmc: PMC7969243
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e682Informations de copyright
Copyright © 2021 The Author(s). Transplantation Direct. Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors declare no funding or conflicts of interest.
Références
Am J Physiol Lung Cell Mol Physiol. 2008 Sep;295(3):L379-99
pubmed: 18621912
Am J Respir Crit Care Med. 1997 Oct;156(4 Pt 1):1099-104
pubmed: 9351608
J Heart Lung Transplant. 1998 Apr;17(4):423-9
pubmed: 9588588
Transplantation. 2020 Sep;104(9):1899-1905
pubmed: 32502131
Nat Protoc. 2008;3(6):1101-8
pubmed: 18546601
PLoS One. 2016 Dec 9;11(12):e0167898
pubmed: 27936178
Crit Care. 2002 Aug;6(4):327-9
pubmed: 12225608
Transplantation. 2011 Jul 27;92(2):163-9
pubmed: 21677599
Am J Respir Cell Mol Biol. 2011 Jan;44(1):34-9
pubmed: 20118224
Lab Anim. 2007 Jul;41(3):363-71
pubmed: 17640464
Eur J Cardiothorac Surg. 2014 Mar;45(3):e54-60
pubmed: 24431161
N Engl J Med. 2011 Apr 14;364(15):1431-40
pubmed: 21488765
Transplant Rev (Orlando). 2018 Oct;32(4):194-206
pubmed: 30049604
J Heart Lung Transplant. 2011 Dec;30(12):1312-9
pubmed: 21930395
Br J Anaesth. 2014 Sep;113(3):346-59
pubmed: 24980425
J Transplant. 2013;2013:521369
pubmed: 23691272
Ann Thorac Surg. 2011 Aug;92(2):478-84
pubmed: 21704971
J Thorac Cardiovasc Surg. 2019 Sep 9;:
pubmed: 31606173
Am J Transplant. 2016 Jan;16(1):33-43
pubmed: 26366523
Crit Care. 2010;14(5):R183
pubmed: 20946631
Am J Respir Crit Care Med. 2002 Jan 15;165(2):211-5
pubmed: 11790657
J Thorac Dis. 2014 Aug;6(8):1039-53
pubmed: 25132971
Am J Transplant. 2005 Apr;5(4 Pt 1):684-93
pubmed: 15760391
Hum Gene Ther. 2017 Sep;28(9):757-765
pubmed: 28052693
J Crit Care. 2013 Feb;28(1):111.e1-7
pubmed: 22762934
Transplantation. 2020 Sep;104(9):e252-e259
pubmed: 32217944
Transpl Int. 2016 Nov;29(11):1237-1246
pubmed: 27514498
J Heart Lung Transplant. 2012 Oct;31(10):1120-6
pubmed: 22975103
J Thorac Dis. 2014 Aug;6(8):1054-62
pubmed: 25132972
Transplantation. 1998 Jun 27;65(12):1533-42
pubmed: 9665067
Anesthesiology. 2009 Feb;110(2):333-41
pubmed: 19194160
J Transl Med. 2014 May 02;12:111
pubmed: 24884924